Naloxegol

CHEMBL2219418 Phase 4 Disetujui Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

651.8 g/mol

LogP

-1.0

Phase

4

This medication is used to treat opioid-induced constipation in adults taking opioid pain medicines for non-cancer pain. It works by blocking opioid receptors specifically in the gut without affecting pain relief in the rest of the body, allowing normal bowel function to resume.

Berat Molekul

651,8000 g/mol

LogP

-1,00

TPSA

127,00 Å²

Lipinski RO5

Gagal

Area Terapeutik

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Pain Management Non-Small Cell Lung Cancer Breast Cancer Chronic Pain Prostate Cancer Colorectal Cancer

Mekanisme Kerja

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanisme

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission …

Struktur 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](OCCOCCOCCOCCOCCOCCOCCOC)CC[C@@]3(O)[C@H]1C5

InChI

InChI=1S/C34H53NO11/c1-3-9-35-10-8-33-30-26-4-5-27(36)31(30)46-32(33)28(6-7-34(33,37)29(35)25-26)45-24-23-44-22-21-43-20-19-42-18-17-41-16-15-40-14-13-39-12-11-38-2/h3-5,28-29,32,36-37H,1,6-25H2,2H3/t28-,29+,32-,33-,34+/m0/s1

Molecular Formula

C34H53NO11

HBD / HBA

2 / 12

Ikatan yang Dapat Dirotasi

24

Atom Berat

46

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

This medication is used to treat opioid-induced constipation in adults taking opioid pain medicines for non-cancer pain. It works by blocking opioid receptors specifically in the gut without affecting pain relief in the rest of the body, allowing normal bowel function to resume.

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Yes, Naloxegol is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2219418. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 56959087. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Mencari informasi yang ramah bagi pasien?

Naloxegol di PillFYI

Struktur

Data Cepat

Rumus: C34H53NO11
Sinonim: 1

Tautan Eksternal

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.